- Market Realist•3 days ago
Novartis (NVS) reported no change in its revenue on a constant currency basis in 2016 compared to 2015. The company's 2016 revenue fell to $48.5 billion.
- Investopedia•3 days ago
Big pharma companies eagerly await key decisions on drugs from the FDA next week.
- Reuters•4 days ago
Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival. Given earlier impressive clinical trial results, investors expect the Food and Drug Administration (FDA) to clear both Roche's multiple sclerosis (MS) treatment Ocrevus and Sanofi's new eczema drug Dupixent.
GSK.L : Summary for GLAXOSMITHKLINE PLC ORD 25P - Yahoo Finance
GlaxoSmithKline plc (GSK.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||1,670.50 x 175400|
|Ask||1,678.00 x 417900|
|Day's Range||1,659.00 - 1,677.17|
|52 Week Range||1,363.00 - 1,745.56|
|PE Ratio (TTM)||90.16|
|Dividend & Yield||1.01 (4.89%)|
|1y Target Est||N/A|